devxlogo

Siemens acquires Dotmatics for $5.1 billion

Siemens acquisition
Siemens acquisition

Siemens AG, a global leader in industrial software, has announced the acquisition of Dotmatics, a provider of scientific data management solutions, in a deal valued at $5.1 billion. The acquisition is part of Siemens’ strategy to expand its presence in the life sciences sector and enhance its digital offerings to the pharmaceutical and biotech industries. Dotmatics specializes in software that helps life science organizations manage, share, and analyze their scientific data.

The company’s applications include automated data ingestion from lab instruments and predictive AI software, which more than 2 million scientists use among 14,000 customers worldwide. “Artificial Intelligence has emerged as a transformative force across various industries, and its application in Life Sciences is becoming increasingly important,” said Siemens President and CEO Roland Busch.

Siemens expands life sciences footprint

The Dotmatics acquisition is part of our ONE Tech Company growth program. It enhances our leading position in industrial software and helps our customers innovate even faster.

The acquisition will add $11 billion to Siemens’ total addressable market goals. Chief Financial Officer Ralf Thomas mentioned that the deal will be financed partially by selling shares in other companies, including Siemens Healthineers, which was spun out in 2017. Following an exciting journey with Insight Partners, where Dotmatics achieved remarkable growth and portfolio expansion, we are thrilled to announce our new chapter with Siemens,” said Dotmatics CEO Thomas Swalla.

Combining our next-generation scientific intelligence platform and industry-leading scientific applications with Siemens’ Digital Twin and AI capabilities, we’ll drive a new wave of innovation in life sciences R&D.

The transaction is expected to close in the third quarter of 2025, pending regulatory approvals and customary closing conditions. Siemens sees the addition of Dotmatics as a significant step in providing more comprehensive solutions that can support the entire drug development lifecycle.

See also  Trump Trade Signal Lifts UK Hopes

Image Credits: Photo by Desola Lanre-Ologun on Unsplash

Cameron is a highly regarded contributor in the rapidly evolving fields of artificial intelligence (AI) and machine learning. His articles delve into the theoretical underpinnings of AI, the practical applications of machine learning across industries, ethical considerations of autonomous systems, and the societal impacts of these disruptive technologies.

About Our Editorial Process

At DevX, we’re dedicated to tech entrepreneurship. Our team closely follows industry shifts, new products, AI breakthroughs, technology trends, and funding announcements. Articles undergo thorough editing to ensure accuracy and clarity, reflecting DevX’s style and supporting entrepreneurs in the tech sphere.

See our full editorial policy.